Has anyone independently verified a QYB survodutide batch COA?

For reference: QYB · survodutide.

Somebody stated this to me confidently and I would like to check it before repeating it.

I would accept a well-reasoned negative answer over a poorly sourced positive one.

What would count as evidence here, and does it exist?

The structural problem with a group buy is that the organiser typically holds both the money and the material, which means there is no point at which any participant has recourse. That is solvable, and it is solved by design rather than by trust.

Cost per milligram, worked honestly: a 10 mg vial at £34 is £3.40 per nominal milligram. If the content assay says 9.2 mg, that is £3.70 per actual milligram. If you then lose 4 µL of dead space per draw from a 2 mL fill across twenty draws, that is 80 µL or four per cent of the fill, taking you to £3.85. Add a £110 content assay amortised across the vial and it is £14.85 per milligram for the first vial of a new lot and £3.85 thereafter. The testing dominates, which is the actual argument for buying larger lots.

Lot-to-lot content variation of nine per cent between two nominally identical lots, both within a stated specification, is the single most common finding in independent testing and the least discussed. It is not fraud; it is the consequence of a fill process controlled to a tolerance rather than to a target. It is also the reason a per-lot content assay is worth more than a per-supplier reputation.

Worth being explicit that this site sells nothing, is not affiliated with any supplier, and has no financial relationship with any vendor discussed. Vendor storefronts are linked from the vendor directory, marked nofollow and sponsored.

The evidence you want is boring: the same result, from an independent laboratory, across more than one lot, over more than one year.

Mechanically, evaluate a supplier on the documentation they cannot fabricate cheaply, which in practice means lot-specific certificates from a laboratory that hosts its own reports and a testing history that spans more than one lot.

The consumer-protection question about a stablecoin transfer has a simple answer: you give up reversibility entirely. There is no chargeback, no acquirer, no dispute process. What you retain is the on-chain record, which proves that a transfer happened and to which address — useful for establishing that you paid, useless for getting the money back. That asymmetry is the whole risk profile.

On declarations: the accurate description of a research reference material is a research reference material, and accuracy is both the legal position and the practical one. A declaration that misdescribes the contents converts a customs question into a different kind of question, and it does so on a document with your name on it.

The economics of pooled purchasing are not specific to this field, and the failure modes documented in the general literature on informal collective purchasing — organiser default, quality dispute without adjudication, and free-riding on testing costs — are exactly the ones that recur here.

Structure the group buy so that no single person is simultaneously the treasurer, the custodian and the arbiter. That one change removes most of the failure modes.

To be exact about it, start from what "research use only" actually means, because most of the downstream questions are answered by it. It means no release testing, no pharmacovigilance, no regulatory obligation to you, and no recourse.

The difference between a batch certificate and a vial certificate is a difference in what is being claimed. A batch certificate says "we tested some vials from this lot". A vial certificate says "we tested this vial". Neither is worthless; only one of them is about the object in your hand, and the gap between them is a sampling assumption nobody has quantified.

The published aggregate datasets from Janoshik, Medutest and PeptideMeter are the closest thing to a systematic evidence base in this space, and the striking pattern across all three is that identity is almost always confirmed, purity is usually acceptable, and content is where the variance lives.

One qualification: independent testing tells you about the vial you sent. It tells you about the vial you kept only under an assumption of homogeneity that nobody has tested.

Assume no recourse and plan accordingly. That assumption is both prudent and, in this context, accurate.

Worth being precise here: the question to ask is not whether a vendor is good but what evidence exists, of what kind, about which lots, from whom. Reputation is a compression of that evidence and it compresses badly.

Personal-importation discretion varies more than people assume. Several jurisdictions operate a published enforcement-discretion policy for small quantities for personal use of unapproved products; several do not, and treat any importation of an unapproved medicinal product as an offence irrespective of quantity. The distinction is jurisdiction-specific and worth checking rather than inferring from a forum consensus.

Where VendorInvestigate has documented verification processes, the value is in the audit trail rather than in the badge, and reading the process description is more informative than reading the outcome.

The limitation of the red-flag approach is that it is asymmetric: it identifies bad documentation reliably and good material only weakly.

If a supplier will not send you a lot-specific certificate before you order, you have learned something useful at zero cost.

edited 13 Aug 2024 by Dr_Aoife_Brennan — corrected a unit error in the worked example